Skip to main content

Position statements

Cancer Australia position statements address significant clinical issues, emerging issues in cancer control and issues of ongoing interest using the best available evidence.
  • Testing for ovarian cancer in asymptomatic women

    Published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    The purpose of this Position Statement is to provide information and guidance in relation to routine screening of women who are at population risk of ovarian cancer, and surveillance of women who are at high or potentially high risk of developing ovarian cancer. The scope encompasses unimodal and multimodal strategies for early detection of ovarian cancer in asymptomatic women. The scope does not include diagnostic testing for assessment of individual women presenting with symptoms. 

  • Genetic testing for women diagnosed with ovarian cancer

    Published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    The purpose of this Position Statement is to provide information and recommendations on genetic testing for women diagnosed with invasive epithelial ovarian cancer, based on available evidence and on consensus. The scope of this Position Statement encompasses genetic testing for heritable, or germline, gene mutations, with a focus on genetic testing of BRCA1 and BRCA2. The intended audiences are health professionals, medical colleges, consumers, media and policy makers.

  • Lung cancer screening using low-dose computed tomography

    Revised & updated:
    First published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    The Australian Government Department of Health's Standing Committee on Screening has considered lung cancer screening and prepared a position statement on lung cancer screening using low-dose computed tomography, released in 2015.

    On the basis of the current evidence and in line with the Population Based Screening Framework, the Standing Committee on Screening does not support an Australian lung cancer screening program, either for the general population or for high risk populations. The Standing Committee on Screening will continue to evaluate and advise on emerging evidence on lung cancer screening. The position statement provides a brief overview of the main points arising from the lung cancer epidemiology literature and explores some key issues related to lung cancer screening in the context of the Australian screening principles.

  • Early detection of breast cancer

    Revised & updated: ,
    First published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    This position statement applies to the early detection of breast cancer in asymptomatic women (women without breast changes). The statement does not apply to diagnostic tests used to assess individual women presenting with breast changes.

  • Lifestyle risk factors and the primary prevention of cancer

    Published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    It is estimated that at least one third of all cancer cases are preventable, and that potentially more than half of all cancers could be avoided through a combination of healthy lifestyle and regular screening. Prevention offers the most cost-effective long-term strategy for the control of cancer across the population.  This positon statement includes recommendations for adults to reduce their risk of cancer and stay healthy.

  • Overdiagnosis from mammographic screening

    Revised & updated: ,
    First published:
    Resource status: Greater than 5 years

    This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.

    Summary:

    This position statement outlines the evidence for mammographic screening and estimates of overdiagnosis. “Overdiagnosis” from breast screening does not refer to error or misdiagnosis, but rather refers to breast cancer diagnosed by screening that would not otherwise have been diagnosed during a woman’s lifetime. “Overdiagnosis” includes all instances where cancers detected through screening (ductal carcinoma in situ or invasive breast cancer) might never have progressed to become symptomatic during a woman’s life, i.e., cancer that would not have been detected in the absence of screening.1 It is not possible to precisely predict at diagnosis, to which cancers overdiagnosis would apply.

  • Cancer clusters

    Published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    National Health and Medical Research Council (NHMRC) has released a position statement to provide information about the assessment and management of cancer clusters. The statement is intended to support guidelines issued by State and Territory Health Departments and Cancer Councils.

  • Overdiagnosis from mammographic screening

    Revised & updated: ,
    First published:
    Resource status: Greater than 5 years

    This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.

    Summary:

    This position statement outlines the evidence for mammographic screening and estimates of overdiagnosis. “Overdiagnosis” from breast screening does not refer to error or misdiagnosis, but rather refers to breast cancer diagnosed by screening that would not otherwise have been diagnosed during a woman’s lifetime. “Overdiagnosis” includes all instances where cancers detected through screening (ductal carcinoma in situ or invasive breast cancer) might never have progressed to become symptomatic during a woman’s life, i.e., cancer that would not have been detected in the absence of screening.1 It is not possible to precisely predict at diagnosis, to which cancers overdiagnosis would apply.

  • Complementary and alternative therapies

    Revised & updated:
    First published:
    Resource status: Cập nhật

    This resource has been developed, reviewed or revised within the last 5 years.

    Summary:

    Although there is some looseness in usage of the terms, complementary therapies refer to those therapies that do not replace or preclude conventional medical therapies, whereas alternative therapies are treatment options outside the orthodox range, that may be used in place of conventional treatments.

  • Hormone Replacement Therapy (HRT) and risk of breast cancer

    Revised & updated:
    First published:
    Resource status: Greater than 5 years

    This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.

    Summary:

    This position statement applies only to Hormone Replacement Therapy (HRT) and breast cancer risk in women – it does not address other risks or benefits to women from HRT usage.

Pages